◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 6086

Fangzhou Inc. (6086) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Pharmaceutical Retailers · DATA UPDATED 2026-08-10

Fangzhou Inc. (6086) operates in the Pharmaceutical Retailers industry and is headquartered in Guangzhou, China with about 494 employees. Its market capitalization is roughly CNY 998 million. In the fiscal year ended 2025-12-31, 6086 reported CNY 3.5B in revenue and CNY 12M in net income.

Fangzhou Inc. provides online chronic disease management services in China. It operates through four segments: Online Retail Pharmacy Services; Comprehensive Medical Services; Wholesale; and Customized Content and Marketing Solutions.

Interactive charts & full statements →

6086 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 3.5BCNY 2.7BCNY 2.4BCNY 2.2B
Gross ProfitCNY 559MCNY 516MCNY 487MCNY 381M
Operating Income (EBIT)CNY 12M(CNY 749M)(CNY 27M)(CNY 127M)
Net IncomeCNY 12M(CNY 855M)(CNY 197M)(CNY 383M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6086 Free Cash Flow History

6086 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 814MCNY 664MCNY 521MCNY 519M
Total LiabilitiesCNY 660MCNY 532MCNY 2.4BCNY 2.2B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6086 viewer.

Other Companies in Pharmaceutical Retailers

← 6083All “0-9” companies6087 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.